DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis

Information source: Amgen
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rheumatoid Arthritis

Intervention: Etanercept (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Amgen

Official(s) and/or principal investigator(s):
MD, Study Director, Affiliation: Amgen

Summary

The purpose of this study is to assess whether DCE-MRI can detect changes of active disease in rheumatoid arthritis (RA) patients after 4, 8 and 12 weeks of etanercept.

Clinical Details

Official title: DCE-MRI of the Wrist to Measure Short-Term Responses in Rheumatoid Arthritis Subjects Treated With Etanercept

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-29

Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-57

Percent Change in Synovial Transfer Constant (Ktrans) From Days 1-85

Percent Change in Synovial Initial Area Under the (Contrast-time) Curve (IAUC) From Days 1-29

Percent Change in the Synovial Initial Area Under the Contrast-Tme Curve (IAUC) From Days 1-57

Percent Change in the Synovial Initial Area Under the Contrast-Time Curve (IAUC) From Days 1-85

Secondary outcome:

Percent Change in Synovial Volume From Days 1-29

Percent Change in Synovial Volume From Days 1-57

Percent Change in Synovial Volume From Days 1-85

Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 29

Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 57

Difference Between Percent Change in Ktrans From Days -28 to 1 and Days 1 to 85

Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 29

Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 57

Difference Between Percent Change in IAUC From Days -28 to 1 and Days 1 to 85

Detailed description: The current literature shows the promise of magnetic resonance imaging (MRI) for assessing response to therapy in RA but the heterogeneity of the methodology and the semi-quantitative nature of the image analysis limits its applicability. To evaluate the ability of DCE-MRI to serve as a biomarker for treatment-induced changes in RA associated synovial inflammation, the reproducibility of the measurement and an effect size are required. Additional endpoints such as synovial volume, bone erosion progression and bone marrow edema-like changes may also prove useful for short-term assessment of a therapeutic intervention, but have not been explored in the context of a pharmacodynamic biomarker. It is therefore critical to conduct a carefully designed longitudinal study, focused on identifying the key parameters related to the instrumentation and data analysis, to fully evaluate the potential utility of MRI in an early clinical development setting. Importantly, this study will also demonstrate the feasibility of using DCE-MRI at multiple centers to acquire useful information that will drive program decisions. Expanded Access: Amgen provides expanded access for this clinical trial. Contact the Amgen Call Center (866-572-6436) for more information.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Fulfillment of the 1987 American College of Rheumatology (ACR) criteria for RA with a

disease duration > 6 months

- Presence of active disease (defined as both tender and swollen joints) in at least

one wrist

- Sub-optimal response to methotrexate (MTX) defined by the presence of the following

criteria (based on 68/66 joint count): 8 or more swollen joints AND 8 or more tender joints (with involvement of the wrist, fingers and at least one region outside the hands) at screening

- Must be receiving MTX at a stable dose > 15 mg/week at least 12 weeks prior to

baseline

- a lower dose is acceptable if otherwise not tolerated (toxicity documentation

required). Exclusion Criteria:

- Patients who are currently receiving disease modifying anti-rheumatic drug (DMARD)

therapy (other than MTX, hydroxychloroquine or sulfasalazine) including tumor necrosis factor (TNF) antagonists (etanercept, infliximab, and adalimumab), abatacept, rituximab, leflunomide, cyclosporine, and gold (oral and intramuscular injection) within 8 weeks or 5. 5 half-lives, whichever is longer, of screening

- Co-existing condition requiring medications that alter vascular flow (e. g., nitrates,

calcium channel blockers, ergot containing drugs) [Potential effects of antihypertensive and migraine medications will be discussed with the Sponsor]

- Comorbid autoimmune disorders including systemic lupus erythematosus

- Unable to undergo an MRI examination (e. g., presence of a pacemaker, defibrillator,

or other implanted device such as anterior interbody cages, aneurysm clip or pedicle screws

- allergic to contrast agent

- tattoos [in area of examination if contains metallic pigment])

- or will likely require sedation for the procedure

Locations and Contacts

Research Site, London, United Kingdom

Research Site, Los Angeles, California, United States

Research Site, Seattle, Washington, United States

Additional Information

AmgenTrials clinical trials website

Starting date: September 2006
Last updated: July 10, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015